Patient-Reported Outcomes of Belzutifan versus Everolimus in Patients with Previously Treated Advanced Renal Cell Carcinoma
In this MEDtalk, Dr. Thomas Powles discusses the quality of life data from the LITESPARK-005 study, a randomised phase III study comparing belzutifan with everolimus for heavily pre-treated patients with metastatic clear cell renal cancer.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
